GHK-Cu is one of the most-searched research peptides on the internet right now, and the most common question we see is the simplest one: how much. This page is a research-grade reference to what the published literature actually says - topical concentrations, subcutaneous μg ranges, frequency, reconstitution math, safety profile and onset timelines.
Everything below is descriptive research context drawn from peer-reviewed sources. GHK-Cu is supplied by New-U Research Compounds as a lyophilised powder for in-vitro and preclinical research use only. Nothing on this page is medical advice or a human-use dosing instruction. For mechanism and study landscape, start with our GHK-Cu research guide.
30-second summary: Topical research formulations: ~1–10 μg per application, 1–2× daily. Subcutaneous research studies: ~50–200 μg per session, 2–3× weekly. Reconstitute with bacteriostatic water (blue tint = copper complex working). Store cold, protect from light. Endogenous tripeptide; not FDA-approved as a drug.
The published research literature converges on two dose ranges, depending on route:
| Route | Typical research range | Frequency | Notes |
|---|---|---|---|
| Topical (cosmetic-chemistry studies) | 1–10 μg per application, in a 0.05–2% formulation | Once or twice daily | Only copper-complexed forms (GHK-Cu and (GHK)₂-Cu) cross the stratum corneum in membrane-model studies. Unliganded GHK shows weaker topical activity. |
| Subcutaneous injection (animal/preclinical studies) | 50–200 μg per session | 2–3 times per week | Plasma half-life of the free tripeptide is under 30 minutes; ~95% cleared after dermal injection. Effects persist through downstream gene expression, not plasma residence. |
| Iontophoresis / microneedle | Equivalent to topical, but with deeper dermal delivery | Per study protocol | Used when researchers want topical-style local action with enhanced penetration. |
The numbers are smaller than people expect because GHK-Cu is active at picomolar to nanomolar concentrations in vitro. It's a signalling tripeptide, not a structural ingredient - it tells fibroblasts what to do, then the cellular response carries the work.
Daily injection is uncommon in the GHK-Cu literature. Most subcutaneous protocols describe 2–3 sessions per week, for two reasons:
Topical formulations are different - they are reapplied once or twice daily because the goal is sustained local exposure of skin fibroblasts.
When subcutaneous injection is used in research models, the standard sites are the same as for other research peptides: lateral abdominal fat (away from the umbilicus), the dorsal subcutaneous space, or the lateral thigh. Site rotation reduces local copper-related discoloration and irritation. Many dermatology and cosmetic-chemistry studies skip injection entirely and use topical or iontophoretic delivery, since the copper complex penetrates the stratum corneum directly.
GHK-Cu ships as a lyophilised (freeze-dried) powder with a faint blue tint from the copper. Reconstitution is straightforward:
For the volume math (how much water to add to hit a target μg per IU on your syringe), use our reconstitution calculator. The volume equation is simply volume = mg / target concentration - it is a math utility, not a dose-calculator that suggests what to inject.
GHK-Cu is an endogenous human tripeptide. Your own plasma contains it: about 200 ng/mL at age 20, declining to around 80 ng/mL by age 60. That endogeneity is the foundation of its safety profile - your body has been clearing GHK and GHK-Cu on its own for decades.
In published research, no serious systemic toxicity has been reported at the dose ranges described above. The copper(II) binding constant (log K ≈ 16.44 at physiological pH) is high enough that GHK-Cu transports copper into cells without triggering the Fenton-chemistry oxidative damage that free copper ions can cause. That is the entire reason copper has to be chaperoned by a peptide carrier in this kind of research.
That said: GHK-Cu is a research compound, not a medicine. New-U makes no human-use claims, supplies material for laboratory research only, and the safety summary above is descriptive research context - not a clearance for self-administration.
No. GHK-Cu is not an FDA-approved drug. Two distinct facts get confused here:
For a longer treatment of how research peptides relate to the FDA's compounding framework, see peptides and FDA approval and are peptides legal.
Published research on GHK-Cu has not identified a carcinogenic signal. The mechanism people sometimes worry about - that anything which stimulates cell growth must also accelerate tumour growth - does not hold here. GHK-Cu's gene-expression effects are regenerative (collagen synthesis, angiogenesis, wound-bed remodelling), and Hong et al. (2012, BioMed Research International) actually showed that the related GHK tripeptide can reset gene expression in metastatic colon-cancer cells toward a more normal, less metastatic profile.
This is not a clearance for any specific clinical or self-use scenario. It is a summary of what the published preclinical literature reports. Any decision to use GHK-Cu in a given research model should be guided by your institution's research-ethics framework and the current peer-reviewed literature.
In research and cosmetic-chemistry contexts, yes - the mechanism is plausible and the literature supports it. GHK-Cu:
Together those mechanisms support its use in studies of post-inflammatory acne marks (PIE / PIH) and atrophic acne-scar remodelling. Effects are reported with sustained topical exposure - usually weeks, not days. Companion peptides like Matrixyl and Argireline are sometimes stacked for multi-pathway skincare research.
Time-to-effect depends on what endpoint you are measuring:
| Endpoint | Reported timeline |
|---|---|
| Fibroblast gene-expression changes in vitro | Hours |
| Wound-bed remodelling in animal models | Days |
| Hair follicle metrics (anagen prolongation, follicle size) | 2–6 weeks |
| Visible skin endpoints (texture, fine-line depth, photoaging markers) in cosmetic studies | 4–12 weeks of sustained topical exposure |
| Sustained dermal density / elasticity changes | 8–12 weeks+ |
For one writer's field note on dermal density changes observed in the field (specifically: a tattoo artist noticing skin density mid-session), see GHK-Cu & skin thickness: a field note from the tattoo chair.
New-U Research Compounds supplies GHK-Cu as a lyophilised, copper-complexed powder in 10-vial research packs at 50 mg or 100 mg per vial. Every batch is independently verified at >99% HPLC purity by Janoshik Analytics and Freedom Diagnostics, with a batch-linked Certificate of Analysis. Direct-from-source pricing, discreet cold-chain shipping (6–14 days worldwide), free shipping over $300, card and cryptocurrency accepted.
10-vial research packs · >99% HPLC purity · Janoshik & Freedom Diagnostics verified · Direct from source.
View GHK-CuGHK-Cu is a research compound. New-U Research Compounds supplies it for in-vitro and preclinical laboratory research only. Nothing on this page is medical advice, a dosing instruction, or a recommendation for human use. Not for human use.